Phase 2 trial of indoximod plus pembrolizumab for advanced melanoma
Dr. Yousef Zakharia
The IDO pathway is a key counter-regulatory mechanism that is exploited by tumors to evade antitumor immunity. A multicenter phase 2 study in the United States evaluated the combination of the IDO pathway inhibitor indoximod and pembrolizumab for advanced melanoma. The objective response rate for the evaluable population was 51% (20% complete response) and the disease control rate was 70%. The median PFS was 12.4 months (95% CI 6.4-24.9). The combination was well tolerated.
